{"organizations": [], "uuid": "fc4820b5bb4280a9f696093fc50ae0e0cf39a015", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180308.html", "section_title": "Archive News &amp; Video for Thursday, 08 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/insys-results/drugmaker-insys-reports-bigger-loss-on-lower-subsys-sales-idUSL4N1QQ5KJ", "country": "US", "domain_rank": 408, "title": "Drugmaker Insys reports bigger loss on lower Subsys sales", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.001, "site_type": "news", "published": "2018-03-09T05:32:00.000+02:00", "replies_count": 0, "uuid": "fc4820b5bb4280a9f696093fc50ae0e0cf39a015"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/insys-results/drugmaker-insys-reports-bigger-loss-on-lower-subsys-sales-idUSL4N1QQ5KJ", "ord_in_thread": 0, "title": "Drugmaker Insys reports bigger loss on lower Subsys sales", "locations": [], "entities": {"persons": [{"name": "sai sachin ravikumar", "sentiment": "none"}, {"name": "john kapoor", "sentiment": "none"}, {"name": "anuron kumar mitra", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "insys therapeutics inc", "sentiment": "negative"}, {"name": "insys", "sentiment": "none"}, {"name": "thomson reuters trust principles", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 8 (Reuters) - Insys Therapeutics Inc reported a bigger fourth-quarter loss compared with a year earlier, hurt by higher costs and soft demand for Subsys, an opioid cancer pain medication at the center of a federal probe of the company.\nThe drugmaker said on Thursday net loss was $47 million or 65 cents per share in the quarter ended Dec. 31, compared with $3.7 million or 5 cents per share, a year earlier.\nRevenue fell 42.6 percent to $31.5 million.\nInsys has been embroiled in legal problems since October last year when founder John Kapoor resigned from Insysâ€™ board of directors after being arrested on charges that he participated in a scheme to bribe doctors to prescribe Subsys. (Reporting by Anuron Kumar Mitra; Editing by Sai Sachin Ravikumar)\nOur Standards: The Thomson Reuters Trust Principles.", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-09T05:32:00.000+02:00", "crawled": "2018-03-09T14:25:30.000+02:00", "highlightTitle": ""}